• Alcohol and Anti-HIV Drugs Exacerbate Stress in Aging Liver

  2026-05-19

  This study investigates how alcohol, anti-HIV drugs, and hippuric acid intensify cellular stress responses in senescent hepatocytes and aging murine liver. By dissecting molecular markers and stress pathways, the research reveals mechanisms of enhanced liver vulnerability in aging populations with HIV and substance use, providing new insights for experimental models and therapeutic risk assessment.

• 0.4% Trypan Blue Solution: Practical Guide for Cell Viabilit

  2026-05-18

  0.4% Trypan Blue Solution provides a reliable method for distinguishing live from dead cells during cell viability and counting assays, ensuring robust discrimination in research workflows. It is specifically designed for laboratory use in viability measurement, cytotoxicity, and apoptosis studies, but is not suitable for diagnostic or clinical applications.

• SMAD3 Inhibition Downregulates ADAMTS-5 in Early Osteoarthri

  2026-05-18

  Xiang et al. (2023) demonstrate that targeted inhibition of SMAD3 using SIS3 reduces ADAMTS-5 expression in early osteoarthritis, likely via upregulation of miRNA-140. These findings refine our understanding of TGF-β/SMAD3 signaling in cartilage degeneration and suggest new investigative directions for OA and fibrosis research.

• Optimizing Cell Assays with Coagulation Factor II (Thrombin)

  2026-05-17

  This article guides biomedical researchers through real lab scenarios where Coagulation Factor II (Thrombin) B Chain Fragment [Homo sapiens] (SKU A1057) boosts reproducibility, sensitivity, and workflow efficiency in cell-based assays. Drawing on validated protocols and comparative insights, we show how A1057 supports robust data and safe, streamlined laboratory procedures.

• Antipyrine in CNS Research: Applied Protocols and Troublesho

  2026-05-16

  Antipyrine (1,5-dimethyl-2-phenylpyrazol-3-one) is the gold-standard reference for blood-brain barrier and pharmacokinetic studies, distinguished by its purity and versatile solubility. This article delivers workflow-driven guidance for deploying Antipyrine in advanced CNS drug research, highlighting actionable protocol enhancements and troubleshooting strategies informed by recent high-throughput BBB modeling breakthroughs.

• Dabigatran Etexilate: Precision Thrombin Inhibition in Resea

  2026-05-15

  Explore Dabigatran etexilate as a direct thrombin inhibitor with unique mechanistic and translational research value. This article reveals advanced assay parameters and decision-making insights not found in standard reviews.

• Quinolone–Coumarin Hybrids Show Anti-Toxoplasma Activity In

  2026-05-15

  This study systematically evaluates novel quinolone–coumarin hybrids, synthesized from fluoroquinolones and novobiocin, for their in vitro anti-parasitic efficacy against Toxoplasma gondii. Select hybrids demonstrated significantly improved selectivity and potency compared to standard therapies, highlighting promising leads for anti-Toxoplasma drug development.

• FITC Goat Anti-Mouse IgG (H+L) Antibody: Evidence, Limits, W

  2026-05-14

  The FITC Goat Anti-Mouse IgG (H+L) Antibody is a fluorescein-conjugated secondary antibody that enables sensitive and specific detection of mouse IgG in immunofluorescence and flow cytometry. Its high-affinity, minimal cross-reactivity, and robust signal amplification make it essential for reliable mouse IgG detection in biomedical research.

• Functional Hepatobiliary Organoids from hiPSCs: Study Insigh

  2026-05-14

  This study presents the first robust protocol for generating functional hepatobiliary organoids entirely from human induced pluripotent stem cells (hiPSCs), without the need for exogenous cells or genetic modification. These organoids recapitulate key aspects of liver and biliary development, offering a promising in vitro model for liver disease research and drug discovery.

• HOBt (1-Hydroxybenzotriazole) in Precision Peptide Synthesis

  2026-05-13

  Unlock superior amide bond formation with HOBt (1-Hydroxybenzotriazole), a trusted racemization inhibitor that preserves stereochemistry even in complex peptide and antibiotic derivative syntheses. APExBIO’s high-purity HOBt streamlines workflows and empowers researchers to minimize epimerization and maximize yield with confidence.

• X-Gal Applications: Precision Blue-White Screening in Clonin

  2026-05-13

  X-Gal, a high-purity chromogenic substrate from APExBIO, powers rapid and reliable blue-white colony screening in molecular cloning. Discover advanced protocol enhancements, troubleshooting insights, and emerging research connecting X-Gal to olfactory gene regulation.

• Ferritin-Based Hybrid Vaccine: Dual Antigen Display for Infl

  2026-05-12

  This study introduces a ferritin-based hybrid protein particle vaccine co-displaying influenza A M2e and SARS-CoV-2 S-protein tandem epitopes, efficiently produced in E. coli. The hybrid particle elicits enhanced and broad humoral responses, offering a promising approach for next-generation combination vaccines.

• Nilotinib (AMN-107) in Kinase-Driven Cancer Research Workflo

  2026-05-12

  Nilotinib (AMN-107) empowers cancer researchers to dissect BCR-ABL and KIT signaling with unrivaled selectivity and reproducibility. This guide translates recent mechanistic breakthroughs into actionable protocols and troubleshooting strategies—enabling robust, data-driven chronic myeloid leukemia and gastrointestinal stromal tumor research.

• Liposomal Co-Delivery of Cisplatin and Procainamide Hydrochl

  2026-05-11

  This study demonstrates that embedding both cisplatin and procainamide hydrochloride in liposomal carriers enhances antiproliferative effects while potentially reducing toxicity in cancer cell models. The findings highlight a mechanistically distinct strategy, leveraging procainamide’s dual roles in cardiac and epigenetic modulation, for improved chemotherapeutic delivery.

• Alfuzosin HCl: Clinical Mechanisms and Evidence in BPH Treat

  2026-05-11

  The reference study provides a comprehensive review of alfuzosin hydrochloride as a functionally uroselective α1 adrenoceptor antagonist for benign prostatic hyperplasia (BPH). It details alfuzosin’s pharmacology, clinical efficacy, and safety profile, offering evidence that supports its use in improving lower urinary tract symptoms with fewer cardiovascular side effects compared to other agents.

539 records 17/36 page Previous Next First page 上5页 1617181920 下5页 Last page